Innoviva (INVA)
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-dail...
- Open
- 20.960
- High
- 21.070
- Low
- 20.800
- Prev. Close
- 20.960
- Volume
- 527.01K
- Turnover
- 11.04M
- Avg Price
- 20.944
- Bid/Ask Ratio
- --
- Amplitude
- 1.29%
- 52wk High
- 25.145
- Volume Ratio
- 0.79
- Turnover Ratio
- 0.78%
Innoviva Analyst Rating
View moreForecast & Rating
Aug 20, 2026Price forecast
$35.0066.91%
Forecast & RatingBuy
4analysts
- Strong buy75.00%
- Buy0.00%
- Hold0.00%
- Sell25.00%
- Strong sell0.00%
News
- Simplywall · 2 days ago, 11:22 AM
Innoviva (INVA) Faces A Valuation Test, Is The Discount Too Wide?
- Global Report · Aug 12 at 05:12 AM
The Infrastructure Illusion: Fusion Energy, IP, and the Messy Tech Back-End
- Market Beat · Aug 7 at 07:48 AM
Cantor Fitzgerald Lowers Innoviva (NASDAQ:INVA) Price Target to $34.00
- Market Beat · Aug 5 at 11:41 PM
Innoviva (NASDAQ:INVA) Announces Quarterly Earnings Results, Misses Expectations By $1.58 EPS
- Earnings Watch · Aug 5 at 03:58 PM
Innoviva | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 119.59 M
- PUBT · Aug 5 at 03:28 PM
Innoviva Q2 FY26 swings to net loss of $83.4 million; revenue rises 19% to $119.6 million
